{"entity": "journal", "iuid": "a1cf0a52eee44e29a01c2d2c206ff16f", "timestamp": "2026-08-26T22:46:41.687Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/journal/Pharmacol%20Res.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/journal/Pharmacol%20Res"}}, "title": "Pharmacol Res", "issn": "1096-1186", "issn-l": null, "publications_count": 3, "publications": [{"entity": "publication", "iuid": "fa3aa1b629d84030bd4756e73f06fc04", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/fa3aa1b629d84030bd4756e73f06fc04.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/fa3aa1b629d84030bd4756e73f06fc04"}}, "title": "The alpha2 nicotinic acetylcholine receptor, a subunit with unique and selective expression in inhibitory interneurons associated with principal cells.", "authors": [{"family": "Hilscher", "given": "Markus M", "initials": "MM"}, {"family": "Mikulovic", "given": "Sanja", "initials": "S"}, {"family": "Perry", "given": "Sharn", "initials": "S"}, {"family": "Lundberg", "given": "Stina", "initials": "S"}, {"family": "Kullander", "given": "Klas", "initials": "K"}], "type": "journal article", "published": "2023-10-00", "journal": {"title": "Pharmacol Res", "issn": "1096-1186", "volume": "196", "pages": "106895", "issn-l": null}, "abstract": "Nicotinic acetylcholine receptors (nAChRs) play crucial roles in various human disorders, with the \u03b17, \u03b14, \u03b16, and \u03b13-containing nAChR subtypes extensively studied in relation to conditions such as Alzheimer's disease, Parkinson's disease, nicotine dependence, mood disorders, and stress disorders. In contrast, the \u03b12-nAChR subunit has received less attention due to its more restricted expression and the scarcity of specific agonists and antagonists for studying its function. Nevertheless, recent research has shed light on the unique expression pattern of the Chrna2 gene, which encodes the \u03b12-nAChR subunit, and its involvement in distinct populations of inhibitory interneurons. This review highlights the structure, pharmacology, localization, function, and disease associations of \u03b12-containing nAChRs and points to the unique expression pattern of the Chrna2 gene and its role in different inhibitory interneuron populations. These populations, including the oriens lacunosum moleculare (OLM) cells in the hippocampus, Martinotti cells in the neocortex, and Renshaw cells in the spinal cord, share common features and contribute to recurrent inhibitory microcircuits. Thus, the \u03b12-nAChR subunit's unique expression pattern in specific interneuron populations and its role in recurrent inhibitory microcircuits highlight its importance in various physiological processes. Further research is necessary to uncover the comprehensive functionality of \u03b12-containing nAChRs, delineate their specific contributions to neuronal circuits, and investigate their potential as therapeutic targets for related disorders.", "doi": "10.1016/j.phrs.2023.106895", "pmid": "37652281", "labels": [], "xrefs": [{"db": "pii", "key": "S1043-6618(23)00251-7"}], "notes": [], "created": "2026-08-21T11:27:26.878Z", "modified": "2026-08-21T11:27:26.890Z"}, {"entity": "publication", "iuid": "0372e5f9d5e3486f9f56fe531fc713f6", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/0372e5f9d5e3486f9f56fe531fc713f6.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/0372e5f9d5e3486f9f56fe531fc713f6"}}, "title": "Antibiotic use and the risk of breast cancer: A systematic review and dose-response meta-analysis.", "authors": [{"family": "Simin", "given": "Johanna", "initials": "J"}, {"family": "Tamimi", "given": "Rulla M", "initials": "RM"}, {"family": "Engstrand", "given": "Lars", "initials": "L"}, {"family": "Callens", "given": "Steven", "initials": "S"}, {"family": "Brusselaers", "given": "Nele", "initials": "N"}], "type": "journal article", "published": "2020-10-00", "journal": {"title": "Pharmacol Res", "issn": "1096-1186", "volume": "160", "pages": "105072", "issn-l": null}, "abstract": "Oral antibiotics are posed as a possible risk factor for breast cancer. Evidence is insufficient to determine whether the choice of antibiotic class could effect this potential association, and non-linearity has not been studied. We aimed to fill these important knowledge gaps.\n\nPubMed, Web of Science, Embase and a trial registry were searched from inception until January 2020, without any restrictions. Additionally, extensive manual searches were undertaken. Random-effects meta-analyses provided pooled risk estimates with 95 % confidence intervals (CI). Dose-response analyses modeling the relationship between number of antibiotic prescriptions and breast cancer risk were extended to non-linear models. Heterogeneity, publication bias and small-study effects were assessed.\n\nOf 7805 identified publications ten were eligible, including 3,719,383 individuals and 84,485 breast cancer cases. The pooled breast cancer risk was modestly increased among individuals who ever used antibiotics (relative risk RR = 1.18, 95 %CI 1.08-1.29), also after excluding the last year prior diagnosis. This excess risk was seen among penicillin (RR = 1.09, 95 %CI 1.01-1.18), tetracycline (RR = 1.13, 95 %CI 1.04-1.24) and nitrofuran users (RR = 1.26, 95 %CI 1.05-1.52), whilst nitroimidazole and metronidazole use (RR = 1.05, 95 %CI 1.00-1.11) indicated for marginal association. No apparent association was found for other antibiotics. Data suggested for a non-linear dose-dependent relationship, with a seemingly protective effect after at least 35 prescriptions. However, these findings might partly be explained by limited power of dose-response analyses.\n\nThe association of antibiotics with breast cancer risk appears to differ between the various antibiotic classes. Whether this association is causal remains unclear, requiring further clarification and mechanistic studies.", "doi": "10.1016/j.phrs.2020.105072", "pmid": "32679181", "labels": [], "xrefs": [{"db": "pii", "key": "S1043-6618(20)31380-3"}], "notes": [], "created": "2026-08-21T11:27:25.030Z", "modified": "2026-08-21T11:27:25.056Z"}, {"entity": "publication", "iuid": "6e869ac7c2a348f68f343f859eb849bd", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/6e869ac7c2a348f68f343f859eb849bd.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/6e869ac7c2a348f68f343f859eb849bd"}}, "title": "Rimeporide as a \ufb01rst- in-class NHE-1 inhibitor: Results of a phase Ib trial in young patients with Duchenne Muscular Dystrophy.", "authors": [{"family": "Previtali", "given": "Stefano C", "initials": "SC"}, {"family": "Gidaro", "given": "Teresa", "initials": "T"}, {"family": "D\u00edaz-Manera", "given": "Jordi", "initials": "J"}, {"family": "Zambon", "given": "Alberto", "initials": "A"}, {"family": "Carnesecchi", "given": "Stephanie", "initials": "S"}, {"family": "Roux-Lombard", "given": "Pascale", "initials": "P"}, {"family": "Spitali", "given": "Pietro", "initials": "P"}, {"family": "Signorelli", "given": "Mirko", "initials": "M"}, {"family": "Szigyarto", "given": "Cristina Al-Khalili", "initials": "CA"}, {"family": "Johansson", "given": "Camilla", "initials": "C"}, {"family": "Gray", "given": "Julian", "initials": "J"}, {"family": "Labolle", "given": "Delphine", "initials": "D"}, {"family": "Porte Thom\u00e9", "given": "Florence", "initials": "F"}, {"family": "Pitchforth", "given": "Jacqueline", "initials": "J"}, {"family": "Domingos", "given": "Joana", "initials": "J"}, {"family": "Muntoni", "given": "Francesco", "initials": "F"}], "type": "clinical trial, phase i", "published": "2020-09-00", "journal": {"title": "Pharmacol Res", "issn": "1096-1186", "volume": "159", "pages": "104999", "issn-l": null}, "abstract": "Rimeporide, a \ufb01rst-in-class sodium/proton exchanger Type 1 inhibitor (NHE-1 inhibitor) is repositioned by EspeRare for patients with Duchenne Muscular Dystrophy (DMD). Historically, NHE-1 inhibitors were developed for cardiac therapeutic interventions. There is considerable overlap in the pathophysiological mechanisms in Congestive Heart Failure (CHF) and in cardiomyopathy in DMD, therefore NHE-1 inhibition could be a promising pharmacological approach to the cardiac dysfunctions observed in DMD. Extensive preclinical data was collected in various animal models including dystrophin-deficient (mdx) mice to characterise Rimeporide's anti-fibrotic and anti-inflammatory properties and there is evidence that NHE-1 inhibitors could play a significant role in modifying DMD cardiac and also skeletal pathologies, as the NHE-1 isoform is ubiquitous. We report here the first study with Rimeporide in DMD patients. This 4-week treatment, open label phase Ib, multiple oral ascending dose study, enrolled 20 ambulant boys with DMD (6-11 years), with outcomes including safety, pharmacokinetic (PK) and pharmacodynamic (PD) biomarkers. Rimeporide was safe and well-tolerated at all doses. PK evaluations showed that Rimeporide was well absorbed orally reaching pharmacological concentrations from the lowest dose, with exposure increasing linearly with dose and with no evidence of accumulation upon repeated dosing. Exploratory PD biomarkers showed positive effect upon a 4-week treatment, supporting its therapeutic potential in patients with DMD, primarily as a cardioprotective treatment, and provide rationale for further efficacy studies.", "doi": "10.1016/j.phrs.2020.104999", "pmid": "32535224", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC7482441"}, {"db": "pii", "key": "S1043-6618(20)31307-4"}], "notes": [], "created": "2026-08-20T08:03:36.473Z", "modified": "2026-08-20T08:03:36.539Z"}], "created": "2026-08-20T08:03:36.499Z", "modified": "2026-08-20T08:03:36.500Z"}